ATE247709T1 - 3'utr des menschliches prohibitin-gens - Google Patents

3'utr des menschliches prohibitin-gens

Info

Publication number
ATE247709T1
ATE247709T1 AT96921425T AT96921425T ATE247709T1 AT E247709 T1 ATE247709 T1 AT E247709T1 AT 96921425 T AT96921425 T AT 96921425T AT 96921425 T AT96921425 T AT 96921425T AT E247709 T1 ATE247709 T1 AT E247709T1
Authority
AT
Austria
Prior art keywords
utr
prohibitin gene
human prohibitin
human
gene
Prior art date
Application number
AT96921425T
Other languages
English (en)
Inventor
Orco Robert T Dell
Eldon R Jupe
J Keith Mcclung
Xiao-Tie Liu
Robert L King
Original Assignee
Oklahoma Med Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Med Res Found filed Critical Oklahoma Med Res Found
Application granted granted Critical
Publication of ATE247709T1 publication Critical patent/ATE247709T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
AT96921425T 1995-06-07 1996-06-07 3'utr des menschliches prohibitin-gens ATE247709T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/473,486 US5922852A (en) 1995-06-07 1995-06-07 3' untranslated region of the human prohibitin gene
PCT/US1996/009687 WO1996040919A1 (en) 1995-06-07 1996-06-07 3' utr of the human prohibitin gene

Publications (1)

Publication Number Publication Date
ATE247709T1 true ATE247709T1 (de) 2003-09-15

Family

ID=23879728

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96921425T ATE247709T1 (de) 1995-06-07 1996-06-07 3'utr des menschliches prohibitin-gens

Country Status (9)

Country Link
US (3) US5922852A (de)
EP (1) EP0837935B1 (de)
AT (1) ATE247709T1 (de)
AU (1) AU713814B2 (de)
CA (1) CA2224014A1 (de)
DE (1) DE69629570T2 (de)
DK (1) DK0837935T3 (de)
ES (1) ES2205046T3 (de)
WO (1) WO1996040919A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922852A (en) * 1995-06-07 1999-07-13 Oklahoma Medical Research Foundation 3' untranslated region of the human prohibitin gene
AU774116B2 (en) * 1995-06-07 2004-06-17 Oklahoma Medical Research Foundation Use of prohibitin RNA in treatment of cancer
AU723400B2 (en) * 1996-11-07 2000-08-24 Oklahoma Medical Research Foundation Diagnostic assay for breast cancer susceptibility
JP2002502584A (ja) * 1997-11-06 2002-01-29 オゥクラホゥマ、メディカル、リサーチ、ファウンデイシャン 癌罹患性の診断アッセイ
JP2002522014A (ja) * 1998-07-24 2002-07-23 オクラホマ メディカル リサーチ ファウンデーション 癌治療におけるプロヒビチンｒｎａの使用法
AU761027B2 (en) * 1998-08-25 2003-05-29 Merck Patent Gmbh Expression and export of angiostatin and endostatin as immunofusis
US7273855B2 (en) * 1999-07-24 2007-09-25 Oklahoma Medical Research Foundation Use of prohibitin RNA in treatment of cancer
US20040002071A1 (en) * 2001-09-19 2004-01-01 Intergenetics, Inc. Genetic analysis for stratification of cancer risk
CA2514184C (en) 2003-01-21 2016-04-12 Ptc Therapeutics, Inc. Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same
US8426194B2 (en) 2003-01-21 2013-04-23 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating VEGF expression
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
US20060246451A1 (en) * 2003-03-19 2006-11-02 Russell James A Plasminogen activator inhibitor-1 (pai-1) haplotypes useful as indicators of patient outcome
JP2006521116A (ja) * 2003-03-27 2006-09-21 ピーティーシー セラピューティクス，インコーポレーテッド 抗真菌性および／または抗増殖性分子を同定するためのｔＲＮＡスプライシング経路の酵素の標的化
EP1613159A4 (de) * 2003-03-27 2007-08-01 Ptc Therapeutics Inc Verfahren zur identifikation von verbindungen mit einer trna-splicenden endonuklease als angriffsort, sowie verwendungen für diese verbindungen als antifungale mittel
US20070020630A1 (en) * 2003-03-27 2007-01-25 Trotta Christopher R Methods of identifying compounds that target trna splicing endonuclease and uses of said compounds as anti-proliferative agents
EP1649002A4 (de) * 2003-07-02 2009-06-03 Ptc Therapeutics Inc Rna prozessierende proteinkomplexe und verwendungen davon
CA2546363A1 (en) * 2003-11-17 2005-06-02 Anuradha Mehta Methods and agents for screening for compounds capable of modulating her2 expression
US8283115B1 (en) 2007-06-20 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating muscular dystrophy using UTRN mRNA translation regulation
US8283116B1 (en) 2007-06-22 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating spinal muscular atrophy using SMN mRNA translation regulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05271294A (ja) * 1992-01-24 1993-10-19 Japan Found Cancer Res ヒトプロヒビチンおよびそれをコードするｄｎａ
US5922852A (en) * 1995-06-07 1999-07-13 Oklahoma Medical Research Foundation 3' untranslated region of the human prohibitin gene

Also Published As

Publication number Publication date
US5776738A (en) 1998-07-07
AU6265396A (en) 1996-12-30
DE69629570D1 (de) 2003-09-25
WO1996040919A1 (en) 1996-12-19
CA2224014A1 (en) 1996-12-19
AU713814B2 (en) 1999-12-09
DE69629570T2 (de) 2004-06-17
EP0837935A1 (de) 1998-04-29
ES2205046T3 (es) 2004-05-01
EP0837935B1 (de) 2003-08-20
US7259251B1 (en) 2007-08-21
DK0837935T3 (da) 2003-12-15
US5922852A (en) 1999-07-13

Similar Documents

Publication Publication Date Title
DE69629570D1 (de) 3'utr des menschliches prohibitin-gens
NZ332720A (en) Therapeutic uses of bactericidal/permeability increasing (BPI) protein to treat human meningococcemia
HK1026144A1 (en) Aryl ureas for the treatment of inflammatory or immunomodulatory diseases.
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
HK1029922A1 (en) Angiostatic agents and compositions for treating glc1a glaucoma
MX9700538A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
IL117177A (en) Benzopyran-containing compounds and their use in manufacture of medicaments for treatment of estrogen sensitive diseases such as endometrical cancer
GB9613003D0 (en) N-oxides of morpholine derivatives and their use as therapeutic agents
MX9707570A (es) Utilizacion de agonistas de alta1l para el tratamiento de la incontinencia urinaria.
MX9703621A (es) Nuevos derivados aminoacidos con actividad mejorada para la resistencia a drogas multiples.
TW362971B (en) Pharmaceutical composition and kit for treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and a S-phase or M-phase specific anti
PL323798A1 (en) Application of derivatives of vitamin d4 in treating skin diseases
DK0687184T3 (da) Rekombinante adenoviruser og anvendelse deraf ved genterapi til behandling af øjensygdomme
IL127739A0 (en) Retinoyloxy (substituted) alkylene butyrates useful for the treatment of cancer and other proliferative diseases
HK1045524A1 (en) 5-Hydroxysapogenin derivatives with anti-dementia activity
IL115320A0 (en) Retinoyloxy (substituted) methyl butyrates useful for the treatment of cancer and other proliferative diseases
NZ512289A (en) Fused heterocyclic compounds and their use in the treatment of neurodegenerative diseases
FI973185A (fi) Melatoniinin käyttö lääkeriippuvuudesta kärsivien potilaiden hoitoon
GEP20012511B (en) Method for Lowering Level of Lipoproteins (a) in Serum or Plasma of Mammals, Method for Treatment of Peripheral Vascular Diseases or Restenosis
AU5672000A (en) Method for detecting the effect of different chemotherapeutic agents and/or radiation therapy in malignant diseases and method for selecting more effective therapeutic agents for the therapy thereof
EP0733365A3 (de) Verwendung von Benzochinolin-3-one zur Behandlung und Vorbeugung von Prostatkarzinom
ES2183977T3 (es) Combinacion de temozolomida y alfa-interferon para el tratamiento de cancer avanzado.
FR2720276B1 (fr) Nouvelle utilisation thérapeutique des agents bétamimétiques et médicament en contenant.
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
GB9704046D0 (en) Arrestable therapeutic

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0837935

Country of ref document: EP

REN Ceased due to non-payment of the annual fee